Consistent with weight model parameters, baseline height (αh) and the decrease in height velocity over time (γh) were also not associated with being overweight.
To investigate in an open-label randomized study, the effect of two doses of growth hormone (GH) on final height and height velocity during the first 2 years of treatment of children with idiopathic short stature (mean baseline height standard deviation score [SDS] −3.2).
Compared with baseline, CMJ height was at least possibly decreased by 2.5 ± 5.5% (straight-line, with chances for greater/similar/lower values of 1/49/50, respectively) and 4.7 ± 7.2% (COD, 1/11/88) after the 1st set, and by 3.6 ± 7.9 (straight-line, 1/30/69) and 2.9 ± 6.9% (COD, 1/25/74) after the second set.
Baseline BMI was calculated as baseline weight (kilograms) divided by the square of baseline height (metres).
Then baseline BMI was calculated as baseline weight divided by baseline height squared (kg/m).
The height of the reach determined the baseline height for the participant.
At baseline, height, body mass index (BMI) and handgrip strength were measured and compared with those in a western reference population.
Baseline height and weight were used to calculate the baseline BMI.
For patients with missing baseline demographics (height [ n = 35], body mass index [ n = 35], creatinine clearance [CrCL] [ n = 13], and body weight [ n = 13]), median values of the population were used.
To further aid clinical interpretation of the intervention effect, analysis of log transformed weight at 12 months postpartum will also be considered, with baseline log weight and log height as covariates.
